1.000000
0.000000
0.000000
0.000000
1.000000
0.000000
0.000000
0.000000
1.000000
0.00000
0.00000
0.00000
THR B 27 - PRO B 28 MODEL 5 OMEGA =220.40 PEPTIDE BOND DEVIATES SIGNIFICANTLY FROM TRANS CONFORMATION
THR B 27 - PRO B 28 MODEL 7 OMEGA =134.22 PEPTIDE BOND DEVIATES SIGNIFICANTLY FROM TRANS CONFORMATION
THR B 27 - PRO B 28 MODEL 8 OMEGA =131.54 PEPTIDE BOND DEVIATES SIGNIFICANTLY FROM TRANS CONFORMATION
Hua, Q.X.
Kochoyan, M.
Weiss, M.A.
http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic
1
90.00
90.00
90.00
1.000
1.000
1.000
C3 H7 N O2
89.093
y
ALANINE
L-peptide linking
C6 H15 N4 O2 1
175.209
y
ARGININE
L-peptide linking
C4 H8 N2 O3
132.118
y
ASPARAGINE
L-peptide linking
C3 H7 N O2 S
121.158
y
CYSTEINE
L-peptide linking
C5 H10 N2 O3
146.144
y
GLUTAMINE
L-peptide linking
C5 H9 N O4
147.129
y
GLUTAMIC ACID
L-peptide linking
C2 H5 N O2
75.067
y
GLYCINE
peptide linking
C6 H10 N3 O2 1
156.162
y
HISTIDINE
L-peptide linking
C6 H13 N O2
131.173
y
ISOLEUCINE
L-peptide linking
C6 H13 N O2
131.173
y
LEUCINE
L-peptide linking
C6 H15 N2 O2 1
147.195
y
LYSINE
L-peptide linking
C9 H11 N O2
165.189
y
PHENYLALANINE
L-peptide linking
C5 H9 N O2
115.130
y
PROLINE
L-peptide linking
C3 H7 N O3
105.093
y
SERINE
L-peptide linking
C4 H9 N O3
119.119
y
THREONINE
L-peptide linking
C9 H11 N O3
181.189
y
TYROSINE
L-peptide linking
C5 H11 N O2
117.146
y
VALINE
L-peptide linking
UK
Nature
NATUAS
0006
0028-0836
354
238
241
10.1038/354238a0
1961250
Receptor binding redefined by a structural switch in a mutant human insulin.
1991
1.000000
0.000000
0.000000
0.000000
1.000000
0.000000
0.000000
0.000000
1.000000
0.00000
0.00000
0.00000
2383.698
INSULIN
1
man
polymer
3343.831
INSULIN
F24G
1
man
polymer
no
no
GIVEQCCTSICSLYQLENYCN
GIVEQCCTSICSLYQLENYCN
A
polypeptide(L)
no
no
FVNQHLCGSHLVEALYLVCGERGGFYTPKT
FVNQHLCGSHLVEALYLVCGERGGFYTPKT
B
polypeptide(L)
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
human
Homo
sample
9606
Homo sapiens
human
Homo
sample
9606
Homo sapiens
repository
Initial release
Version format compliance
Version format compliance
1
0
1994-01-31
1
1
2008-03-24
1
2
2011-07-13
Y
1992-02-28
REL
REL
9
1
HAVEL
refinement
DGII
BRUNGER
refinement
X-PLOR
GLY
1
n
1
GLY
1
A
ILE
2
n
2
ILE
2
A
VAL
3
n
3
VAL
3
A
GLU
4
n
4
GLU
4
A
GLN
5
n
5
GLN
5
A
CYS
6
n
6
CYS
6
A
CYS
7
n
7
CYS
7
A
THR
8
n
8
THR
8
A
SER
9
n
9
SER
9
A
ILE
10
n
10
ILE
10
A
CYS
11
n
11
CYS
11
A
SER
12
n
12
SER
12
A
LEU
13
n
13
LEU
13
A
TYR
14
n
14
TYR
14
A
GLN
15
n
15
GLN
15
A
LEU
16
n
16
LEU
16
A
GLU
17
n
17
GLU
17
A
ASN
18
n
18
ASN
18
A
TYR
19
n
19
TYR
19
A
CYS
20
n
20
CYS
20
A
ASN
21
n
21
ASN
21
A
PHE
1
n
1
PHE
1
B
VAL
2
n
2
VAL
2
B
ASN
3
n
3
ASN
3
B
GLN
4
n
4
GLN
4
B
HIS
5
n
5
HIS
5
B
LEU
6
n
6
LEU
6
B
CYS
7
n
7
CYS
7
B
GLY
8
n
8
GLY
8
B
SER
9
n
9
SER
9
B
HIS
10
n
10
HIS
10
B
LEU
11
n
11
LEU
11
B
VAL
12
n
12
VAL
12
B
GLU
13
n
13
GLU
13
B
ALA
14
n
14
ALA
14
B
LEU
15
n
15
LEU
15
B
TYR
16
n
16
TYR
16
B
LEU
17
n
17
LEU
17
B
VAL
18
n
18
VAL
18
B
CYS
19
n
19
CYS
19
B
GLY
20
n
20
GLY
20
B
GLU
21
n
21
GLU
21
B
ARG
22
n
22
ARG
22
B
GLY
23
n
23
GLY
23
B
GLY
24
n
24
GLY
24
B
PHE
25
n
25
PHE
25
B
TYR
26
n
26
TYR
26
B
THR
27
n
27
THR
27
B
PRO
28
n
28
PRO
28
B
LYS
29
n
29
LYS
29
B
THR
30
n
30
THR
30
B
author_defined_assembly
2
dimeric
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
1_555
x,y,z
identity operation
0.0000000000
0.0000000000
0.0000000000
6
B
B
THR
PRO
27
28
-139.60
8
B
B
THR
PRO
27
28
134.22
9
B
B
THR
PRO
27
28
131.54
1
B
ARG
22
0.317
SIDE CHAIN
2
B
ARG
22
0.275
SIDE CHAIN
3
B
ARG
22
0.304
SIDE CHAIN
4
B
ARG
22
0.317
SIDE CHAIN
5
B
ARG
22
0.287
SIDE CHAIN
6
B
ARG
22
0.288
SIDE CHAIN
7
B
ARG
22
0.320
SIDE CHAIN
8
B
ARG
22
0.208
SIDE CHAIN
9
B
ARG
22
0.192
SIDE CHAIN
1
-4.41
0.60
121.00
116.59
A
A
A
CB
CG
CD2
TYR
TYR
TYR
19
19
19
N
1
3.85
0.60
121.00
124.85
A
A
A
CB
CG
CD1
TYR
TYR
TYR
19
19
19
N
1
9.86
1.10
114.20
124.06
A
A
A
CA
CB
SG
CYS
CYS
CYS
20
20
20
N
1
-5.33
0.60
121.00
115.67
B
B
B
CB
CG
CD2
TYR
TYR
TYR
16
16
16
N
1
7.26
0.60
121.00
128.26
B
B
B
CB
CG
CD1
TYR
TYR
TYR
16
16
16
N
1
9.61
1.10
114.20
123.81
B
B
B
CA
CB
SG
CYS
CYS
CYS
19
19
19
N
2
-4.01
0.60
121.00
116.99
A
A
A
CB
CG
CD2
TYR
TYR
TYR
19
19
19
N
2
3.75
0.60
121.00
124.75
A
A
A
CB
CG
CD1
TYR
TYR
TYR
19
19
19
N
2
-4.96
0.60
121.00
116.04
B
B
B
CB
CG
CD2
TYR
TYR
TYR
16
16
16
N
2
5.69
0.60
121.00
126.69
B
B
B
CB
CG
CD1
TYR
TYR
TYR
16
16
16
N
2
8.26
1.10
114.20
122.46
B
B
B
CA
CB
SG
CYS
CYS
CYS
19
19
19
N
3
-4.58
0.60
121.00
116.42
A
A
A
CB
CG
CD2
TYR
TYR
TYR
19
19
19
N
3
4.98
0.60
121.00
125.98
A
A
A
CB
CG
CD1
TYR
TYR
TYR
19
19
19
N
3
-7.13
0.60
121.00
113.87
B
B
B
CB
CG
CD2
TYR
TYR
TYR
16
16
16
N
3
7.44
0.60
121.00
128.44
B
B
B
CB
CG
CD1
TYR
TYR
TYR
16
16
16
N
3
6.82
1.10
114.20
121.02
B
B
B
CA
CB
SG
CYS
CYS
CYS
19
19
19
N
4
-3.76
0.60
121.00
117.24
A
A
A
CB
CG
CD2
TYR
TYR
TYR
19
19
19
N
4
4.25
0.60
121.00
125.25
A
A
A
CB
CG
CD1
TYR
TYR
TYR
19
19
19
N
4
-4.21
0.60
121.00
116.79
B
B
B
CB
CG
CD2
TYR
TYR
TYR
16
16
16
N
4
5.14
0.60
121.00
126.14
B
B
B
CB
CG
CD1
TYR
TYR
TYR
16
16
16
N
4
8.07
1.10
114.20
122.27
B
B
B
CA
CB
SG
CYS
CYS
CYS
19
19
19
N
5
-4.90
0.60
121.00
116.10
A
A
A
CB
CG
CD2
TYR
TYR
TYR
19
19
19
N
5
4.21
0.60
121.00
125.21
A
A
A
CB
CG
CD1
TYR
TYR
TYR
19
19
19
N
5
12.14
1.10
114.20
126.34
A
A
A
CA
CB
SG
CYS
CYS
CYS
20
20
20
N
5
-6.38
0.60
121.00
114.62
B
B
B
CB
CG
CD2
TYR
TYR
TYR
16
16
16
N
5
7.42
0.60
121.00
128.42
B
B
B
CB
CG
CD1
TYR
TYR
TYR
16
16
16
N
5
8.27
1.10
114.20
122.47
B
B
B
CA
CB
SG
CYS
CYS
CYS
19
19
19
N
6
6.77
1.10
114.20
120.97
A
A
A
CA
CB
SG
CYS
CYS
CYS
11
11
11
N
6
-4.51
0.60
121.00
116.49
A
A
A
CB
CG
CD2
TYR
TYR
TYR
19
19
19
N
6
3.91
0.60
121.00
124.91
A
A
A
CB
CG
CD1
TYR
TYR
TYR
19
19
19
N
6
6.67
1.10
114.20
120.87
A
A
A
CA
CB
SG
CYS
CYS
CYS
20
20
20
N
6
-5.28
0.60
121.00
115.72
B
B
B
CB
CG
CD2
TYR
TYR
TYR
16
16
16
N
6
5.90
0.60
121.00
126.90
B
B
B
CB
CG
CD1
TYR
TYR
TYR
16
16
16
N
7
-5.15
0.60
121.00
115.85
B
B
B
CB
CG
CD2
TYR
TYR
TYR
16
16
16
N
7
5.77
0.60
121.00
126.77
B
B
B
CB
CG
CD1
TYR
TYR
TYR
16
16
16
N
8
8.24
1.10
114.20
122.44
A
A
A
CA
CB
SG
CYS
CYS
CYS
20
20
20
N
8
-4.77
0.60
121.00
116.23
B
B
B
CB
CG
CD2
TYR
TYR
TYR
16
16
16
N
8
6.00
0.60
121.00
127.00
B
B
B
CB
CG
CD1
TYR
TYR
TYR
16
16
16
N
9
4.04
0.60
121.00
125.04
A
A
A
CB
CG
CD1
TYR
TYR
TYR
19
19
19
N
9
-4.00
0.60
121.00
117.00
B
B
B
CB
CG
CD2
TYR
TYR
TYR
16
16
16
N
9
4.14
0.60
121.00
125.14
B
B
B
CB
CG
CD1
TYR
TYR
TYR
16
16
16
N
1
A
SER
9
-128.66
-162.73
1
A
CYS
11
-127.45
-165.27
1
A
GLN
15
-42.82
-78.33
1
B
SER
9
142.49
-59.79
1
B
CYS
19
-104.83
43.45
1
B
GLU
21
34.42
-146.87
1
B
PHE
25
-126.72
-52.29
1
B
THR
27
-131.74
-72.35
2
A
ILE
2
-23.34
-46.68
2
A
VAL
3
-29.96
-46.09
2
A
GLU
4
-25.41
-44.82
2
A
SER
9
118.15
-162.59
2
A
CYS
11
45.33
-162.15
2
A
SER
12
-114.84
-162.28
2
A
GLN
15
-42.24
-80.95
2
B
ASN
3
104.32
169.69
2
B
SER
9
112.34
-55.86
2
B
ARG
22
91.48
-62.20
2
B
PRO
28
-92.46
-81.19
3
A
SER
9
-114.86
-159.67
3
A
ILE
10
-97.38
-60.64
3
A
CYS
11
80.92
-177.70
3
A
GLN
15
-60.22
-70.58
3
A
LEU
16
-72.38
40.05
3
A
CYS
20
-135.00
-54.77
3
B
SER
9
110.57
-30.52
3
B
CYS
19
-110.13
-79.39
3
B
ARG
22
-120.58
-70.87
3
B
TYR
26
-18.46
172.70
3
B
PRO
28
-61.36
78.28
4
A
GLU
4
-93.16
34.82
4
A
THR
8
-137.67
-48.52
4
A
SER
9
-124.13
-158.74
4
A
GLN
15
-56.14
-74.60
4
A
LEU
16
-49.82
-17.84
4
A
CYS
20
-3.76
-54.46
4
B
ASN
3
-115.88
69.72
4
B
GLU
21
-15.25
-63.27
4
B
TYR
26
-112.42
-168.94
4
B
PRO
28
-61.55
90.24
5
A
GLU
4
-89.88
44.82
5
A
CYS
6
-36.50
-31.80
5
A
THR
8
-98.54
59.57
5
A
SER
9
120.96
-158.69
5
A
SER
12
-116.26
-166.97
5
A
TYR
14
-27.44
-61.36
5
A
GLN
15
-43.74
-71.77
5
A
CYS
20
-125.13
-54.96
5
B
ASN
3
99.47
44.08
5
B
CYS
7
-119.44
-159.32
5
B
SER
9
117.34
-58.95
5
B
CYS
19
-109.48
52.97
5
B
ARG
22
-116.98
-77.39
5
B
PHE
25
-104.45
71.07
6
A
GLU
4
-98.78
34.64
6
A
SER
9
-124.29
-150.87
6
A
CYS
11
89.89
-169.53
6
A
SER
12
-118.62
-167.88
6
A
GLN
15
-47.89
-71.45
6
A
LEU
16
-68.72
12.34
6
A
TYR
19
-90.26
58.90
6
B
GLU
21
-112.82
75.89
6
B
PHE
25
-134.65
-62.84
6
B
THR
27
-124.23
-59.55
6
B
PRO
28
-9.27
-151.35
7
A
ILE
2
-24.61
-49.06
7
A
GLU
4
-95.68
44.05
7
A
CYS
7
-91.16
-74.31
7
A
SER
9
-135.83
-143.05
7
A
CYS
11
-121.28
-169.47
7
A
SER
12
-115.42
-158.33
7
A
CYS
20
-8.21
159.11
7
B
SER
9
95.85
-37.80
7
B
LEU
11
-47.62
-73.66
7
B
ARG
22
-114.92
50.73
7
B
PRO
28
-68.36
12.17
8
A
ILE
2
-20.97
-49.66
8
A
VAL
3
-24.17
-43.17
8
A
GLU
4
-24.11
-52.96
8
A
SER
9
-128.19
-156.29
8
A
CYS
11
-117.91
-161.38
8
A
GLN
15
-34.70
-73.67
8
A
LEU
16
-64.44
18.68
8
A
CYS
20
-107.22
-73.69
8
B
ASN
3
137.18
70.02
8
B
SER
9
94.24
-40.67
8
B
CYS
19
-104.15
40.66
8
B
GLU
21
12.78
95.62
9
A
VAL
3
-24.28
-43.57
9
A
GLU
4
-21.28
-55.57
9
A
THR
8
-95.07
56.25
9
A
SER
9
120.02
-167.20
9
A
CYS
11
-127.22
-160.16
9
A
LEU
16
-90.99
47.51
9
B
SER
9
109.28
-44.30
9
B
LEU
11
-49.13
-75.15
9
B
PHE
25
-130.80
-49.89
model building
X-PLOR
refinement
X-PLOR
phasing
X-PLOR
INSULIN (HUMAN) MUTANT WITH PHE B 24 REPLACED BY GLY (F24G) (NMR, REPRESENTATIVE PLUS 8 STRUCTURES)
Receptor binding redefined by a structural switch in a mutant Human Insulin
1
N
N
2
N
N
A
GLU
4
A
GLU
4
HELX_P
A
SER
9
A
SER
9
1
1
6
A
GLN
15
A
GLN
15
HELX_P
A
TYR
19
A
TYR
19
5
2
5
B
LEU
11
B
LEU
11
HELX_P
B
CYS
19
B
CYS
19
1
3
9
disulf
2.018
A
CYS
6
A
SG
CYS
6
1_555
A
CYS
11
A
SG
CYS
11
1_555
disulf
2.021
A
CYS
7
A
SG
CYS
7
1_555
B
CYS
7
B
SG
CYS
7
1_555
disulf
2.022
A
CYS
20
A
SG
CYS
20
1_555
B
CYS
19
B
SG
CYS
19
1_555
HORMONE
HORMONE
INS_HUMAN
UNP
1
90
P01308
INS_HUMAN
UNP
2
25
P01308
90
110
1HIT
1
21
P01308
A
1
1
21
25
54
1HIT
1
30
P01308
B
2
1
30
2
PHE
ENGINEERED MUTATION
GLY
24
1HIT
B
P01308
UNP
48
24
1
P 1